Articles On Actinogen Medical (ASX:ACW)

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade.   WINNERS Scr...

In FY21 the ASX 200 returned over 20 per cent but the 100 best performing ASX stocks all gained over 390 per cent and made an average gain of 821 per cent. Stockhead has compiled a list (see below) of the 100 best performing ASX stocks base...

Over the past month, a number of US FDA approvals have moved the share prices of global pharma stocks, including those traded here on the ASX. The biggest FDA announcement during the month came out of US-based Biogen, which received a contr...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

In early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and tumbling lower. At the time of writing, the benchmark index is down 0.4% to 7,310.8 points. Four ASX shares that have not let that hold them back today are l...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The Actinogen Medical Ltd (ASX: ACW) share price has been a strong performer on Wednesday morning. At the time of writing, the shares of the biotechnology company developing an innovative treatment for cognitive impairment are up 17% to 17...

Shares in Actinogen Medical Ltd (ASX: ACW) soared today after the company released news on the upcoming study of its drug designed to treat Alzheimer’s disease. At market close, the Actinogen share price was trading at 16 cents – 19.23% hi...

Summary The ASX 200 closed sharply lower by 133.60 points or 1.81% at 7,235.30. The market witnessed a sharp, heavy sell-off on persistent concerns over hawkish outlook by the US Federal Reserve. All four big four lenders - Westpac, C...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Whether it’s ultimately justified or not, the US Food and Drug Administration’s approval of an apparently less-than-effective drug for Alzheimer’s disease has created a ripple of excitement around the sector. This is evidenced by a mob call...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week As we appro...

Recent advances in our still-shallow understanding of the human brain have led to a renewed interest in companies that focus on neuroscience. The most famous neuroscience startup, Elon Musk’s Neuralink, is probably the first company that co...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Coming up to the halfway mark of 2021, it is worth reflecting on what ASX shares have been the biggest moneymakers of the year so far. Some of these companies you might know, some you might not. But if you invested at the start of the year...

The Actinogen Medical Ltd (ASX: ACW) share price has been an investor’s dream of late, rising 414% in the last 3 months and 552% over the last 12 months. With a raft of good news for the biotechnology company lately, we take a closer look....

Peter Switzer sits down with the CEO and Managing Director of Actinogen Medical (ACW), Dr Steven Gourlay.

Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength Index (RSI). The RSI is a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the le...

ShareCafeAlzheimer’s Decision Sends Positive Message to Aussie Biotechs The US Food and Drug Administration’s landmark but controversial approval of a new treatment for Alzheimer’s disease suggests a sea change in the regulator’s attitude t...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Cogstate (ASX:CGS) has become the latest ASX health stock to gain from an FDA green light even though it is only indirectly involved – right now. Overnight the US regulator approved the first Alzheimer’s therapy since 2003 and the first dru...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week It has been...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Last month, the ASX finally reached its pre-pandemic high, went in circles for a couple of weeks then reached it again. What else happened in May? Well, the phase “To the moon” obtained its traditional meaning once more. While the phase has...

Investors will be watching for updates on Traka Resources (ASX:TKL) this week, after the gold explorer ripped higher on no news to post an RSI reading of 91. Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Re...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

Google April 2021 and the first things you’ll find isn’t ASX winners but questions about COVID-19. Just another month in the pandemic, right? Well, yes and no. On one hand the vaccine race continues across the world – far slower than we’d l...

Summary Pharmaxis Ltd and Charlie Teo Foundation have identified a new drug that shows promise in tackling a deadly form of brain cancer. Pharmaxis’ PXS-5505 will be a part of preclinical testing to assess its efficacy for glioblastoma...

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

Actinogen Medical Ltd (ASX: ACW) shares are tumbling today after the company released its quarterly activity report and strategic update this morning. At the time of writing, the Actinogen share price is sliding a whopping 17.24% to 4.8 ce...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

Actinogen Medical Ltd (ASX: ACW) shares are rocketing higher today and have now gained 165% since the start of 2021. At the time of writing, the Actinogen share price is trading 23.26% higher for the day so far at 5.3 cents, up from just 2...

March got off to a rough start, with ASX small caps suffering their worst week since October and the Small Ords Index falling into the red on the year. But it got better. US punters received another stimmy cheque in the mail from President...

Stockhead’s Hot Money Monday analysis is based on the Relative Strength Index (RSI) — a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the level at which a company may have been...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

2021 is set to be another big year for ASX capital raisings with solid volumes so far in 2021. In the first nine weeks of the new year, ASX companies have raised over $1.96 billion. Although this is lower than the $3 billion raised in the f...

Actinogen Medical CEO Dr Bill Ketelbey speaks at the Switzer Small and Micro Cap Virtual Investor Day 2020.

The Actinogen Medical Ltd (ASX: ACW) share price jumped 4.5% on open this morning, after the company announced it has filed two new patent applications to strengthen and extend its intellectual property (IP) portfolio.   What does Actinoge...

Actinogen (ASX:ACW) has reveals plans for two clinical trials it will conduct next year - against MCI due to Alzheimers ... Read More The post Actinogen reveals its next clinical trial plans appeared first on Stockhead.

ASX-listed Actinogen Medical is in front of potential investors seeking a $10 million equity injection to fund a trial for its Alzheimer's drug. 

Actinogen Medical (ASX:ACW’) has announced the appointment of Mr Jeff Carter as its new chief financial officer (CFO).

A quick wrap of the key winners and losers on Tuesday, June 2. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day.   Code Name Price % Chg...

From the bulging file of Nasty Obscure Diseases we present idiopathic intracranial hypertension (IIH), a condition characterised by debilitating chronic daily headaches and in some cases severe vision impairment. It’s a poorly treated condi...

The COVID-19 pandemic has led to 527 clinical trials being shut down in Australia and New Zealand the last two months, up 36 per cent on the prior two months as many organisations deem the patient risk of exposure to be too high. Globally,...